{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:37:53Z","timestamp":1770741473531,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.dmpk.2019.11.001","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T16:54:04Z","timestamp":1577206444000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification of non-P450 enzymes involved in the metabolism of new drugs: Their significance in drug interaction evaluation and prodrug disposition"],"prefix":"10.1016","volume":"35","author":[{"given":"Yumi","family":"Nishiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Kazui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dmpk.2019.11.001_bib1","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1208\/s12248-016-9962-6","article-title":"Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance","volume":"18","author":"Argikar","year":"2016","journal-title":"AAPS"},{"key":"10.1016\/j.dmpk.2019.11.001_bib2","series-title":"Labor and welfare, pharmaceutical safety and environmental health Bureau. Guideline on drug interaction for drug development and appropriate provision of information","author":"Japan ministry of health","year":"2018"},{"key":"10.1016\/j.dmpk.2019.11.001_bib4","author":"European Medicines Agency"},{"issue":"1","key":"10.1016\/j.dmpk.2019.11.001_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2125.1998.00050.x","article-title":"Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase","volume":"46","author":"Diasio","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.dmpk.2019.11.001_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00003495-200969080-00009","article-title":"Atazanavir: a review of its use in the management of HIV-1 infection","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.dmpk.2019.11.001_bib8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1124\/dmd.114.058107","article-title":"In\u00a0vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase","volume":"42","author":"Choughule","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2019.11.001_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.0306-5251.2001.01417.x","article-title":"Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B\/1D agonist: differential effects of propranolol, nadolol and metoprolol","volume":"52","author":"Goldberg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2019.11.001_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/j.1875-9114.1985.tb03413.x","article-title":"An update on sodium valproate","volume":"5","author":"Rimmer","year":"1985","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.dmpk.2019.11.001_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jac\/39.2.295","article-title":"Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem\/betamipron","volume":"39","author":"Nagai","year":"1997","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.dmpk.2019.11.001_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/42.4.563","article-title":"Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin","volume":"42","author":"De Turck","year":"1998","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.dmpk.2019.11.001_bib13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/03602530701690341","article-title":"Interaction between valproic acid and carbapenem antibiotics","volume":"39","author":"Mori","year":"2007","journal-title":"Drug Metab Rev"},{"issue":"6","key":"10.1016\/j.dmpk.2019.11.001_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1211\/0022357011776171","article-title":"Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats","volume":"53","author":"Torii","year":"2001","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2019.11.001_bib15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0090-9556(24)15311-1","article-title":"Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats","volume":"27","author":"Yamamura","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmpk.2019.11.001_bib16","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.42.12.3136","article-title":"Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats","volume":"42","author":"Kojima","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.dmpk.2019.11.001_bib17","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/jps.20338","article-title":"Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human","volume":"94","author":"Omoda","year":"2005","journal-title":"J\u00a0Pharm Sci"},{"issue":"12","key":"10.1016\/j.dmpk.2019.11.001_bib18","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0090-9556(24)13678-1","article-title":"Panipenum, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats","volume":"28","author":"Yamamura","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmpk.2019.11.001_bib19","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1124\/dmd.110.032938","article-title":"Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics","volume":"38","author":"Suzuki","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmpk.2019.11.001_bib20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/00498254.2011.596582","article-title":"Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid","volume":"41","author":"Suzuki","year":"2011","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmpk.2019.11.001_bib21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s13318-017-0413-2","article-title":"Observation of clinically relevant drug interaction in chimeric mice with humanized livers: the case of valproic acid and carbapenem antibiotics","volume":"42","author":"Suzuki","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"24","key":"10.1016\/j.dmpk.2019.11.001_bib22","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1158\/1078-0432.CCR-11-1002","article-title":"A\u00a0phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors","volume":"17","author":"Rosen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.dmpk.2019.11.001_bib23","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1002\/cncr.27582","article-title":"Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial","volume":"118","author":"Wagner","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.dmpk.2019.11.001_bib24","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3109\/00498254.2014.926572","article-title":"Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats","volume":"44","author":"Murai","year":"2014","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.dmpk.2019.11.001_bib25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3109\/00498254.2016.1144896","article-title":"Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in\u00a0vitro metabolism of tivantinib","volume":"46","author":"Nishiya","year":"2016","journal-title":"Xenobiotica"},{"issue":"24","key":"10.1016\/j.dmpk.2019.11.001_bib26","first-page":"3936","article-title":"Medium- and short-chain dehydrogenase\/reductase gene and protein families : medium-chain and short-chain dehydrogenases\/reductases in retinoid metabolism","volume":"65","author":"Par\u00e9s","year":"2008","journal-title":"Chem Biol Interact"},{"issue":"1\u20133","key":"10.1016\/j.dmpk.2019.11.001_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cbi.2010.12.005","article-title":"Oxidation of methanol, ethylene glycol, and isopropanol with human alcohol dehydrogenases and the inhibition by ethanol and 4-methylpyrazole","volume":"191","author":"Lee","year":"2011","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.dmpk.2019.11.001_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0079-6603(00)64008-4","article-title":"Regulation of the mammalian alcohol dehydrogenase genes","volume":"64","author":"Edenberg","year":"2000","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"issue":"9","key":"10.1016\/j.dmpk.2019.11.001_bib29","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1007\/s10620-007-0153-2","article-title":"The activity of class I, II, III, and IV alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in liver cancer","volume":"53","author":"Jelski","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.dmpk.2019.11.001_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1440-1819.2011.02190.x","article-title":"Genetics of alcohol dependence","volume":"65","author":"Kimura","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"10.1016\/j.dmpk.2019.11.001_bib31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1530-0277.2001.tb02242.x","article-title":"Gender differences in pharmacokinetics of alcohol","volume":"25","author":"Baraona","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"10.1016\/j.dmpk.2019.11.001_bib32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1389200033489253","article-title":"Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist","volume":"4","author":"Beaumont","year":"2003","journal-title":"Curr Drug Metabol"},{"issue":"10","key":"10.1016\/j.dmpk.2019.11.001_bib33","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm0303812","article-title":"Lessons learned from marketed and investigational prodrugs","volume":"47","author":"Ettmayer","year":"2004","journal-title":"J\u00a0Med Chem"},{"issue":"2 Suppl","key":"10.1016\/j.dmpk.2019.11.001_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.taap.2005.01.046","article-title":"Toxicological implications of esterases--from molecular structures to functions","volume":"207","author":"Satoh","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2019.11.001_bib35","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jps.20542","article-title":"Enzymes involved in the bioconversion of ester-based prodrugs","volume":"95","author":"Liederer","year":"2006","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.dmpk.2019.11.001_bib36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2133\/dmpk.DMPK-12-RV-042","article-title":"The emerging role of human esterases","volume":"27","author":"Fukami","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2019.11.001_bib37","series-title":"Hydrolysis in drug and prodrug metabolism: chemistry, biochemistry, and enzymology","author":"Testa","year":"2003"},{"issue":"6","key":"10.1016\/j.dmpk.2019.11.001_bib38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1358\/dot.2008.44.6.1219543","article-title":"Amlodipine\/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine\/olmesartan combination","volume":"44","author":"Chrysant","year":"2008","journal-title":"Drugs Today"},{"issue":"9","key":"10.1016\/j.dmpk.2019.11.001_bib39","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2165\/00003495-200868090-00005","article-title":"Olmesartan medoxomil: a review of its use in the management of hypertension","volume":"68","author":"Scott","year":"2008","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.dmpk.2019.11.001_bib40","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1517\/14656566.2010.510834","article-title":"Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide","volume":"11","author":"Rump","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.dmpk.2019.11.001_bib41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/11206770-000000000-00000","article-title":"Olmesartan medoxomil\/amlodipine\/hydrochlorothiazide: fixed-dose combination in hypertension","volume":"71","author":"Deeks","year":"2011","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.dmpk.2019.11.001_bib42","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","article-title":"The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction","volume":"19","author":"Laeis","year":"2001","journal-title":"J\u00a0Hypertens Suppl"},{"issue":"16","key":"10.1016\/j.dmpk.2019.11.001_bib43","doi-asserted-by":"crossref","first-page":"11892","DOI":"10.1074\/jbc.M109.072629","article-title":"Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine","volume":"285","author":"Ishizuka","year":"2010","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.dmpk.2019.11.001_bib44","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1124\/dmd.113.051482","article-title":"Interindividual variability of carboxymethylenebutenolidase homolog, a novel olmesartan medoxomil hydrolase, in the human liver and intestine","volume":"41","author":"Ishizuka","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2019.11.001_bib45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/dmd.111.041475","article-title":"Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism","volume":"40","author":"Ishizuka","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmpk.2019.11.001_bib46","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.bbapap.2007.05.001","article-title":"Stability of highly purified human paraoxonase (PON1): association with human phosphate binding protein (HPBP) is essential for preserving its active conformation(s)","volume":"1774","author":"Rochu","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"17\u201318","key":"10.1016\/j.dmpk.2019.11.001_bib47","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jchromb.2009.11.027","article-title":"Integrative analytical approach by capillary electrophoresis and kinetics under high pressure optimized for deciphering intrinsic and extrinsic cofactors that modulate activity and stability of human paraoxonase (PON1)","volume":"878","author":"Renault","year":"2010","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"16","key":"10.1016\/j.dmpk.2019.11.001_bib48","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1517\/14656566.9.16.2893","article-title":"Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development","volume":"9","author":"Angiolillo","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"10.1016\/j.dmpk.2019.11.001_bib49","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1124\/dmd.106.014522","article-title":"The disposition of prasugrel, a novel thienopyridine, in humans","volume":"35","author":"Farid","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2019.11.001_bib50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/11594600-000000000-00000","article-title":"Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients","volume":"12","author":"Tcheng","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"10.1016\/j.dmpk.2019.11.001_bib51","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.112.201640","article-title":"Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation","volume":"344","author":"Zhu","year":"2013","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.dmpk.2019.11.001_bib52","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1124\/dmd.107.020248","article-title":"The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2","volume":"36","author":"Williams","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2019.11.001_bib53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/09537100600565551","article-title":"Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans","volume":"17","author":"Asai","year":"2006","journal-title":"Platelets"},{"issue":"1","key":"10.1016\/j.dmpk.2019.11.001_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1124\/dmd.115.066290","article-title":"Human intestinal raf kinase inhibitor protein (RKIP) catalyzes prasugrel as a bioactivation hydrolase","volume":"44","author":"Kazui","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2019.11.001_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/dmd.115.068221","article-title":"Arylacetamide deacetylase is responsible for activation of prasugrel in human and dog","volume":"44","author":"Kurokawa","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmpk.2019.11.001_bib56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/bi00119a022","article-title":"Importance of phosphatidylethanolamine for association of protein kinase C and other cytoplasmic proteins with membranes","volume":"31","author":"Bazzi","year":"1992","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.dmpk.2019.11.001_bib57","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1128\/MCB.20.9.3079-3085.2000","article-title":"Mechanism of suppression of the Raf\/MEK\/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein","volume":"20","author":"Yeung","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"21","key":"10.1016\/j.dmpk.2019.11.001_bib58","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1128\/MCB.21.21.7207-7217.2001","article-title":"Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation","volume":"21","author":"Yeung","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"15","key":"10.1016\/j.dmpk.2019.11.001_bib59","doi-asserted-by":"crossref","first-page":"13061","DOI":"10.1074\/jbc.M210015200","article-title":"Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein","volume":"278","author":"Corbit","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"6966","key":"10.1016\/j.dmpk.2019.11.001_bib60","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nature02158","article-title":"Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2","volume":"426","author":"Lorenz","year":"2003","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.dmpk.2019.11.001_bib61","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/jcp.24335","article-title":"RKIP: much more than Raf kinase inhibitory protein","volume":"228","author":"Al-Mulla","year":"2013","journal-title":"J\u00a0Cell Physiol"},{"issue":"2","key":"10.1016\/j.dmpk.2019.11.001_bib62","first-page":"62","article-title":"PDGF BB purified from osteoclasts acts as osteoblastogenesis inhibitory factor (OBIF)","volume":"13","author":"Kubota","year":"2002","journal-title":"J\u00a0Biomol Tech"},{"issue":"36","key":"10.1016\/j.dmpk.2019.11.001_bib63","doi-asserted-by":"crossref","first-page":"37832","DOI":"10.1074\/jbc.M400089200","article-title":"Identification of 2'-phosphodiesterase, which plays a role in the 2-5A system regulated by interferon","volume":"279","author":"Kubota","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"28","key":"10.1016\/j.dmpk.2019.11.001_bib64","doi-asserted-by":"crossref","first-page":"24765","DOI":"10.1074\/jbc.M110.217299","article-title":"Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes","volume":"286","author":"Yonesu","year":"2011","journal-title":"J\u00a0Biol Chem"},{"issue":"10","key":"10.1016\/j.dmpk.2019.11.001_bib65","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nbt.1566","article-title":"Sensitive multiplexed analysis of kinase activities and activity-based kinase identification","volume":"27","author":"Kubota","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"6966","key":"10.1016\/j.dmpk.2019.11.001_bib66","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature02166","article-title":"Proteomic characterization of the human centrosome by protein correlation profiling","volume":"426","author":"Andersen","year":"2003","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.dmpk.2019.11.001_bib67","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/ml100301k","article-title":"Discovery of CS-0777: a potent, selective, and orally active S1P1 agonist","volume":"2","author":"Nishi","year":"2011","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"10.1016\/j.dmpk.2019.11.001_bib68","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1074\/mcp.M112.023853","article-title":"Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling","volume":"12","author":"Sakurai","year":"2013","journal-title":"Mol Cell Proteom"},{"issue":"5","key":"10.1016\/j.dmpk.2019.11.001_bib69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0002-9343(74)90631-7","article-title":"Perspectives on alkaline phosphatase isoenzymes","volume":"56","author":"Fishman","year":"1974","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.dmpk.2019.11.001_bib70","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1042\/bj1080779","article-title":"Purification and properties of molecular-weight variants of human placental alkaline phosphatase","volume":"108","author":"Ghosh","year":"1968","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.dmpk.2019.11.001_bib71","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1042\/bj1410103","article-title":"Purification of human placental alkaline phosphatase. Salt effects in affinity chromatography","volume":"141","author":"Doellgast","year":"1974","journal-title":"Biochem J"},{"issue":"15","key":"10.1016\/j.dmpk.2019.11.001_bib72","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1016\/S0021-9258(19)41155-1","article-title":"Bovine kidney alkaline phosphatase. Purification, subunit structure, and metalloenzyme properties","volume":"250","author":"Cathala","year":"1975","journal-title":"J\u00a0Biol Chem"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436719302320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436719302320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:55:47Z","timestamp":1761162947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436719302320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1347436719302320"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2019.11.001","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of non-P450 enzymes involved in the metabolism of new drugs: Their significance in drug interaction evaluation and prodrug disposition","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2019.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}